Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)
NCT02920450
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Signed Institutional Review Board (IRB)-approved informed consent prior to any study-related procedures
- Age of 18 years or older
- Advanced-stage unresectable NSCLC, as confirmed by pathological and/or radiological analysis (subjects will be classified as having advanced disease if they were not eligible for, or had disease progression after, surgical or locoregional therapies)
- Prior chemotherapy will be allowed for other invasive malignancies, provided therapy was completed at least five years before the start of protocol therapy, and participants have recovered from all toxicities of that prior therapy
- Participants may have received prior chemotherapy for NSCLC
- In the Phase II portion, subjects must have disease which lacks PTEN expression by immunohistochemistry, or has known prior activating PI3K or inactivating PTEN gene mutations (mutations will not be assayed for specifically)
- Eastern Cooperative Oncology Group (ECOG) performance status score < 2
- Life expectancy ≥ 12 week
- Participants must have measureable disease by RECIST criteria
- Absolute neutrophil count > 1500 mm3 (individuals with benign ethnic neutropenia may be enrolled if they have no evidence of infectious diathesis, or febrile neutropenia at the time of enrollment)
- Platelet count ≥ 100×109 L
- Hgb ≥ 8.5 g/dL (subjects may receive transfusions to achieve this, in the absence of overt bleeding)
- Total Bilirubin ≤ 2 mg/dL
- aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 3 times the upper limit of normal range
- Serum creatinine ≤1.5 times the upper limit of the normal range
- Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 6 months after the last dose of study drug to minimize the risk of pregnancy. Prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy. WOCBP include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who is not post-menopausal. Post-menopause is defined as:
- Amenorrhea that has lasted for ≥ 12 consecutive months without another cause, or
- For women with irregular menstrual periods who are taking hormone replacement therapy (HRT), a documented serum follicle-stimulating hormone (FSH) level of greater than 35 mIU/mL.
- Males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 6 months following the last dose of study drug
- Uncontrolled cardiac disease, congestive heart failure, angina, arrhythmias or
hypertension.
- Myocardial infarction or unstable angina within 2 months of treatment.
- Known human immunodeficiency virus (HIV) infection or chronic active Hepatitis B
(subjects will not be screened for this).
- Active clinically serious infection > CTCAE Grade 2.
- Thrombotic or embolic events such as a cerebrovascular accident including transient
ischemic attacks within the past 6 months.
- Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks of first dose of
study drug.
- Any other hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks of first dose of
study drug.
- Serious non-healing wound, ulcer, or bone fracture.
- Evidence or history of bleeding diathesis or coagulopathy
- Major surgery, open biopsy or significant traumatic injury within 4 weeks of first
study drug
- Women or men of childbearing potential who are unwilling or unable to use an
acceptable method to avoid pregnancy for the entire study period and for at least 6
months after the last dose of study drug
- Women who are pregnant or breastfeeding.
- History of any other disease, metabolic dysfunction, physical examination finding, or
clinical laboratory finding giving reasonable suspicion of a disease or condition that
contraindicates the use of protocol therapy or that might affect the interpretation of
the results of the study or that puts the subject at high risk for treatment
complications, in the opinion of the treating physician.
- Prisoners or subjects who are involuntarily incarcerated.
- Subjects who are compulsorily detained for treatment of either a psychiatric or
physical illness.
- Subjects demonstrating an inability to comply with the study and/or follow-up
procedures.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Gainesville, Florida
- Gothenburg,
- Jönköping,
- Kalmar,
- Linköping,
- Lund,
- Malmö,
- Skövde,
- Trollhättan,
- Uddevalla,
- Umeå,
- Uppsala,
- Ystad,
- Örebro,
- St. Louis, Missouri
- Boston, Massachusetts
- Middletown, New Jersey
- Pompton Plains, New Jersey
- Commack, New York
- Harrison, New York
- New York, New York
- New York, New York
- Uniondale, New York
- Houston, Texas
- Via Albertoni, Bologna
- Via Albertoni, Bologna
- Via Massarenti, Bologna
- Via Massarenti, Bologna
- Via Massarenti, Bologna
- Via Palagi, Bologna
- Milan, Lombardia
- Milan, Lombardia
- Milan, Lombardia
- Milan, Lombardia
- Milan, Lombardia
- Milan, Lombardia
- Milan, Lombardia
- Viale Pansini, Napli
- Amsterdam, Noord-holland
- Amsterdam,
- Groningen,
- Groningen,
- Cordoba,
- Los Angeles, California
- Santa Monica, California
- Norwich, Connecticut
- Norwich, Connecticut
- Altamonte Springs, Florida
- Bonita Springs, Florida
- Bradenton, Florida
- Brandon, Florida
- Cape Coral, Florida
- Clearwater, Florida
- Fleming Island, Florida
- Fort Myers, Florida
- Fort Myers, Florida
- Gainesville, Florida
- Largo, Florida
- Lecanto, Florida
- Naples, Florida
- New Port Richey, Florida
- Ocala, Florida
- Orange City, Florida
- Orlando, Florida
- Port Charlotte, Florida
- Saint Petersburg, Florida
- Saint Petersburg, Florida
- Sarasota, Florida
- Sarasota, Florida
- Spring Hill, Florida
- Tallahassee, Florida
- Tallahassee, Florida
- Tampa, Florida
- Tavares, Florida
- The Villages, Florida
- Venice, Florida
- Winter Park, Florida
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Johns Creek, Georgia
- Chicago, Illinois
- Overland Park, Kansas
- Baltimore, Maryland
- Baltimore, Maryland
- Baltimore, Maryland
- Baltimore, Maryland
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Chelsea, Massachusetts
- Stoneham, Massachusetts
- Stoneham, Massachusetts
- Creve Coeur, Missouri
- Independence, Missouri
- Kansas City, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- Basking Ridge, New Jersey
- Hackensack, New Jersey
- Montvale, New Jersey
- Bronx, New York
- Bronx, New York
- Bronx, New York
- New York, New York
- New York, New York
- New York, New York
- Durham, North Carolina
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Gahanna, Ohio
- Lewis Center, Ohio
- Clackamas, Oregon
- Newberg, Oregon
- Portland, Oregon
- Portland, Oregon
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- York, Pennsylvania
- Chattanooga, Tennessee
- Chattanooga, Tennessee
- Chattanooga, Tennessee
- Cleveland, Tennessee
- Dickson, Tennessee
- Franklin, Tennessee
- Gallatin, Tennessee
- Hendersonville, Tennessee
- Hermitage, Tennessee
- Lebanon, Tennessee
- Murfreesboro, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Shelbyville, Tennessee
- Smyrna, Tennessee
- Houston, Texas
- Houston, Texas
- Kingwood, Texas
- Shenandoah, Texas
- The Woodlands, Texas
- Seattle, Washington
- Faenza, Emilia-romagna
- Lugo, Emilia-romagna
- Ravenna, Emilia-romagna
- Ravenna, Emilia-romagna
- Rimini, Emilia-romagna
- Roma, Lazio
- Milano, Lombardia
- Napoli, Naples
- Cattolica, Rimini
- Orbassano, Torino
- Orbassano, Torino
- Orbassano, Torino
- Orbassano, Torino
- Orbassano, Torino
- Orbassano, Torino
- Orbassano, Torino
- Milano,
- Napoli,
- Torino,
- Goyang-si, Gyeonggido
- Jeonnam,
- Seoul,
- Seoul,
- Seoul,
- Amsterdam, Noord-holland
- Majadahonda, Madrid
- Malaga, Málaga
- Barcelona,
- Barcelona,
- Barcelona,
- Barcelona,
- Barcelona,
- Cordoba,
- Cordoba,
- Esplugues de Llobregat,
- Hospitalet de Llobregat,
- L'Hospitalet,
- Madrid,
- Madrid,
- Malaga,
- Sevilla,
- Sevilla,
- Sevilla,
Descriptive Information | |||||
---|---|---|---|---|---|
Brief Title ICMJE | Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) | ||||
Official Title ICMJE | A Non-Randomized Phase Ib-II Protocol of Paclitaxel, Carboplatin and the Dual PI3K/mTOR Kinase Inhibitor, PF-05212384, for Patients With Advanced, or Metastatic Non-Small Cell Carcinoma of the Lung | ||||
Brief Summary | The purpose of this research study is to determine if the study drug, Gedatolisib (PF-05212384), given in combination with paclitaxel and carboplatin will work against unresectable non-small cell lung cancer. | ||||
Detailed Description | Approximately 70% of patients with unresectable non-small cell lung cancer (NSCLC) who receive and progress through frontline chemotherapy will be eligible for second line treatments. Any of the agents which are available for frontline therapy can be used in the salvage setting, though only erlotinib, docetaxel, and pemetrexed (in non-squamous cell carcinoma) are FDA-approved in the salvage setting based upon their demonstrated survival benefit in randomized phase III trials. All three appear to be roughly equivalent in terms of clinical benefit, which is admittedly modest, with response rates <10%, clinical benefit rates of approximately 50%, and overall survivals of approximately 6 months. Still, a substantial number of patients may not benefit from the agents in the salvage treatment setting, thus it is critical to identify those patients who stand to benefit the most. The study will consist of two phases, Ib and II. The phase Ib portion will study dose escalations in separate 3+3 cohorts using escalating doses of PF-05212384. The phase II portion will consist of a two stage Simon design. The doses for paclitaxel (200 mg/m2, Q21 days) and carboplatin (AUC=6, Q21 days) do not adjust as part of the study design. The dose of PF-05212384 will be determined during the Phase Ib portion. The primary endpoint of the phase Ib portion of this protocol is to determine a tolerable phase II dose of PF-05212384 in combination with paclitaxel and carboplatin. The primary endpoint of the phase II portion of this study is to determine the objective response rate of disease to the administration of PF-05212384 in combination with paclitaxel and carboplatin. A secondary endpoint of this study will be progression-free survival following PF-05212384 therapy. | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 Phase 2 | ||||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Sequential Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||
Condition ICMJE | Non-Small Cell Lung Cancer | ||||
Intervention ICMJE |
| ||||
Study Arms ICMJE |
| ||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
Recruitment Information | |||||
Recruitment Status ICMJE | Terminated | ||||
Actual Enrollment ICMJE | 3 | ||||
Original Estimated Enrollment ICMJE | 41 | ||||
Actual Study Completion Date ICMJE | April 4, 2019 | ||||
Actual Primary Completion Date | January 2, 2019 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||
Sex/Gender ICMJE |
| ||||
Ages ICMJE | 18 Years to 90 Years (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT02920450 | ||||
Other Study ID Numbers ICMJE | IRB201601181 -A WI211924 ( Other Identifier: Pfizer Inc. ) UF-STO-LUNG-002 ( Other Identifier: University of Florida ) OCR15075 ( Other Identifier: University of Florida ) | ||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product |
| ||||
IPD Sharing Statement ICMJE |
| ||||
Responsible Party | University of Florida | ||||
Study Sponsor ICMJE | University of Florida | ||||
Collaborators ICMJE | Pfizer | ||||
Investigators ICMJE |
| ||||
PRS Account | University of Florida | ||||
Verification Date | October 2019 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |